In this issue:
Peginterferon beta-1a improves MRI measures and increases the proportion of patients with NEDA in RRMS
Long-term effects of dimethyl fumarate in RRMS
NEDA status over long-term follow-up in MS patients treated with interferon beta-1a
Lesion remyelinating activity of GSK239512 in patients with RRMS
MRZ reaction as a marker of MS
Selection of first-line MS therapy using risk-benefit decision analysis
High-dose immunosuppressive therapy and autologous HCT for RRMS
Disease course after CIS in children vs adults
Increasing the sensitivity of MRI MS lesion detection by long axial coverage of the spinal cord
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced MS
Please login below to download this issue (PDF)